Shares of ADMA Biologics Inc (NASDAQ: ADMA) have received an average recommendation of “Hold” from the five ratings firms currently covering the stock, according to MarketBeat Ratings.
The breakdown of analyst opinions shows a divided view, with one investment analyst rating the stock with a sell recommendation.
Two analysts have assigned a hold recommendation to the stock, contributing to the overall consensus rating.
The remaining analysts covering ADMA round out the five-firm total tracked by MarketBeat Ratings in its assessment.
The “Hold” consensus reflects a cautious stance from the analyst community toward the plasma-derived biologics company at this time.
A sell rating from one firm signals at least some concern among analysts about the stock’s near-term performance potential.
The two hold ratings suggest the majority of analysts see limited movement in either direction for ADMA shares in the current environment.
MarketBeat Ratings compiles recommendations across multiple brokerages to provide investors with an aggregated view of analyst sentiment.
ADMA Biologics trades on the NASDAQ exchange under the ticker symbol ADMA, giving retail and institutional investors broad access to the stock.
Investors tracking ADMA will likely watch for any shifts in analyst coverage that could move the consensus rating away from its current “Hold” position.